1. Phylogeny  
   Tyrosine‐protein kinase JAK3 is one of four members of the Janus kinase family that, according to seminal kinome surveys, evolved from a common ancestor in the metazoan lineage (babon2014themolecularregulation pages 1-3, wilks2008thejakkinases pages 1-1). JAK3 is grouped with JAK1, JAK2, and TYK2 and is classified as a non‐receptor tyrosine kinase. Its expression is largely limited to hematopoietic cells, particularly lymphoid lineages, which distinguishes it from the ubiquitously expressed JAK1, JAK2, and TYK2. Homologs of JAK3 can be identified in all mammalian species, and the evolutionary relationships among the JAKs indicate divergence after gene duplication events early in vertebrate evolution (babon2014themolecularregulation pages 3-4, ungureanu2005posttranslationalmodificationsin pages 11-14).
2. Reaction Catalyzed  
   JAK3 catalyzes the transfer of a phosphate group from ATP to specific tyrosine residues on substrate proteins. In its basic reaction, ATP and a protein substrate containing a tyrosine residue are converted to ADP and a phosphorylated protein, thereby converting the tyrosine residue into phosphotyrosine. The reaction can be summarized as:  
     ATP + [protein]-Tyr → ADP + [protein]-Tyr-phosphate + H⁺  
   This reaction is critical in mediating signaling events downstream of cytokine receptors (babon2014themolecularregulation pages 1-3).
3. Cofactor Requirements  
   The catalytic activity of JAK3, like that of many kinases, is dependent on divalent metal ions, most commonly magnesium (Mg²⁺). The Mg²⁺ ion coordinates with ATP in the active site, thereby facilitating the phosphotransfer reaction (alexander2015theconciseguide pages 1-2).
4. Substrate Specificity  
   JAK3 shows substrate specificity in the context of cytokine receptor signaling. It phosphorylates specific tyrosine residues on the cytoplasmic tails of receptors that share the common gamma chain (γc) and on downstream signaling effectors such as the STAT proteins. In the case of interleukin-2 receptor (IL2R) signaling, for example, JAK3 works in tandem with JAK1 by phosphorylating tyrosine residues on IL2Rβ and IL2RG, thereby creating docking sites for STAT5A and STAT5B. Although an explicit consensus substrate motif for JAK3 is not provided in the available literature, its substrate specificity is defined by the receptor complex context and the presence of motifs that promote STAT recruitment (babon2014themolecularregulation pages 14-15, ungureanu2005posttranslationalmodificationsin pages 11-14).
5. Structure  
   JAK3 is organized into several conserved domains that collectively define its function and regulation. Its N-terminal region contains the FERM domain, which is essential for binding to the membrane-proximal regions of cytokine receptors such as IL2R, IL4R, IL7R, IL9R, IL15R, and IL21R (babon2014themolecularregulation pages 4-6, ungureanu2005posttranslationalmodificationsin pages 11-14). Adjacent to the FERM domain is an SH2-like domain, which, although not a classical phosphotyrosine-binding SH2 domain, contributes to maintaining the structural integrity and receptor association of the kinase.  
   Following the receptor-binding modules is a pseudokinase domain (often referred to as JH2). Despite lacking full catalytic activity due to alterations in conserved motifs (for example, substitutions in the β3 strand lysine or the HxD motif), the pseudokinase domain plays a critical regulatory role by modulating the activity of the adjacent catalytic domain. Structural studies indicate that this domain not only participates in autoinhibition via intramolecular interactions (in cis) or possibly trans interactions among receptor-bound complexes but also binds nucleotides that serve as a molecular switch (babon2014themolecularregulation pages 4-6, wilks2008thejakkinases pages 5-6, bailey2014biochemicalanalysisof pages 29-33).  
   The C-terminal region comprises the active kinase domain (JH1). This domain has the classical protein tyrosine kinase bi-lobed structure, with the small N-terminal lobe and a larger C-terminal lobe forming the ATP-binding pocket. Key catalytic features include a well-defined activation loop whose phosphorylation is required for full catalytic activity, a hydrophobic spine, and a C-helix that participates in the reorganization of the active site during conformational changes. Although high-resolution structures specific for full-length JAK3 are not yet available, comparisons with structural data from other JAK family members (such as TYK2 and JAK2) provide a robust framework for modelling JAK3’s architecture (wilks2008thejakkinases pages 4-5, babon2014themolecularregulation pages 7-9, loris2007exploringstructureand pages 49-52).
6. Regulation  
   JAK3 is regulated at multiple levels that ensure proper signal fidelity upon cytokine stimulation. Receptor engagement by cytokines induces conformational changes that facilitate the juxtaposition of receptor-bound JAK molecules, thereby promoting transphosphorylation of key tyrosine residues in the activation loop (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 28-29). In addition to phosphorylation, regulatory mechanisms include:

• Autoinhibition mediated by the pseudokinase (JH2) domain. The JH2 domain is instrumental in maintaining low basal activity by either engaging the active kinase domain in cis or through trans inhibitory interactions between JAK molecules within receptor complexes (babon2014themolecularregulation pages 6-7, babon2014themolecularregulation pages 7-9).

• Negative feedback by suppressor proteins such as the SOCS family. SOCS proteins, particularly SOCS1 and SOCS3, can bind to phosphorylated tyrosine residues on JAKs or associated receptors, thereby blocking further kinase activity and promoting ubiquitin-mediated degradation of signaling components (ungureanu2005posttranslationalmodificationsin pages 14-16, piessevaux2008socsproteinsand pages 18-22).

• Dephosphorylation by protein tyrosine phosphatases, including CD45, TCPTP, and others. These phosphatases remove activating phosphates from the JAK activation loop and other regulatory sites, contributing to signal termination and ensuring that JAK3 is not constitutively active (ungureanu2005posttranslationalmodificationsin pages 9-11, safhi2008primingofstat1 pages 14-21).

Together, these regulatory mechanisms ensure that JAK3 activity is tightly coupled to extracellular cytokine signals, preventing aberrant activation that could lead to pathological states (babon2014themolecularregulation pages 14-15, ungureanu2005posttranslationalmodificationsin pages 16-18).

1. Function  
   JAK3 functions as a central mediator in cytokine receptor signaling pathways that control immune cell development, differentiation, and function. Its activity is indispensable in the signaling cascades initiated by cytokines that utilize the common gamma chain (γc), including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (babon2014themolecularregulation pages 14-15, ungureanu2005posttranslationalmodificationsin pages 11-14). Upon cytokine binding to the respective receptor, JAK3 partners with JAK1 bound to other subunits (for example, IL2RB and IL2RG in the IL2 receptor complex) to phosphorylate receptor cytoplasmic tails, creating phosphotyrosine docking sites for STAT proteins. Subsequent phosphorylation of STAT5A and STAT5B leads to their dimerization and nuclear translocation where they activate transcription of cytokine-responsive genes (babon2014themolecularregulation pages 1-3, mitra2010identificationofa pages 15-23).  
   The expression of JAK3 is largely confined to cells within immune tissues such as T cells, B cells, natural killer cells, and myeloid cells. Loss-of-function mutations in JAK3 result in severe combined immunodeficiency (SCID), underscoring its non-redundant function in lymphoid development and adaptive immunity (babon2014themolecularregulation pages 9-11, ungureanu2005posttranslationalmodificationsin pages 63-65). Furthermore, activating mutations—reported in domains such as the FERM and pseudokinase regions—have been linked to hematological malignancies like acute megakaryocytic leukemia, highlighting the clinical importance of precise JAK3 regulation (babon2014themolecularregulation pages 4-6, wilks2008thejakkinases pages 9-10).
2. Other Comments  
   JAK3 is a recognized therapeutic target, particularly in the context of immune dysregulation and autoimmune diseases. Small molecule inhibitors, including agents such as tofacitinib (CP690,550), have been developed to target JAK3 (often in combination with inhibition of JAK1) with the aim of modulating cytokine signaling in inflammatory and transplant settings (wilks2008thejakkinases pages 6-8, babon2014themolecularregulation pages 26-28). Inhibitory compounds generally target the conserved ATP-binding site within the kinase domain; however, achieving absolute specificity for JAK3 remains challenging due to the high structural homology with other JAK family members (alexander2015theconciseguide pages 10-13, wilks2008thejakkinases pages 9-9).  
   Disease associations with JAK3 include severe combined immunodeficiency (resulting from loss-of-function mutations) as well as various leukemias where activating mutations may lead to uncontrolled proliferation of hematopoietic cells (babon2014themolecularregulation pages 11-13, ungureanu2005posttranslationalmodificationsin pages 65-68). Clinical development of JAK inhibitors continues as therapeutic strategies are refined to maximize efficacy in immune modulation while minimizing adverse effects commonly associated with broad immunosuppression (wilks2008thejakkinases pages 8-9).
3. References
4. babon2014themolecularregulation pages 1-3
5. babon2014themolecularregulation pages 3-4
6. babon2014themolecularregulation pages 4-6
7. babon2014themolecularregulation pages 7-9
8. babon2014themolecularregulation pages 9-11
9. babon2014themolecularregulation pages 14-15
10. babon2014themolecularregulation pages 26-28
11. ungureanu2005posttranslationalmodificationsin pages 9-11
12. ungureanu2005posttranslationalmodificationsin pages 11-14
13. ungureanu2005posttranslationalmodificationsin pages 14-16
14. ungureanu2005posttranslationalmodificationsin pages 16-18
15. ungureanu2005posttranslationalmodificationsin pages 63-65
16. ungureanu2005posttranslationalmodificationsin pages 65-68
17. wilks2008thejakkinases pages 1-1
18. wilks2008thejakkinases pages 3-4
19. wilks2008thejakkinases pages 4-5
20. wilks2008thejakkinases pages 5-6
21. wilks2008thejakkinases pages 6-8
22. wilks2008thejakkinases pages 9-9
23. alexander2015theconciseguide pages 1-2
24. alexander2015theconciseguide pages 10-13
25. mitra2010identificationofa pages 15-23
26. piessevaux2008socsproteinsand pages 18-22
27. safhi2008primingofstat1 pages 14-21
28. loris2007exploringstructureand pages 49-52

References

1. (babon2014themolecularregulation pages 4-6): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
2. (ungureanu2005posttranslationalmodificationsin pages 11-14): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
3. (wilks2008thejakkinases pages 5-6): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
4. (alexander2015theconciseguide pages 1-2): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
5. (alexander2015theconciseguide pages 10-13): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
6. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
7. (babon2014themolecularregulation pages 11-13): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
8. (babon2014themolecularregulation pages 14-15): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
9. (babon2014themolecularregulation pages 26-28): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
10. (babon2014themolecularregulation pages 9-11): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
11. (bailey2014biochemicalanalysisof pages 29-33): F Bailey. Biochemical analysis of human cancer-associated pseudokinases. Unknown journal, 2014.
12. (piessevaux2008socsproteinsand pages 18-22): J Piessevaux. Socs proteins and cytokine signalling: the many faces of the socs box. Unknown journal, 2008.
13. (safhi2008primingofstat1 pages 14-21): MMA Safhi. Priming of stat1 and stat3 for cytokine-triggered degradation by the proteasome upon a2aadenosine receptor (a2aar) expression. Unknown journal, 2008.
14. (ungureanu2005posttranslationalmodificationsin pages 14-16): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
15. (ungureanu2005posttranslationalmodificationsin pages 16-18): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
16. (ungureanu2005posttranslationalmodificationsin pages 63-65): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
17. (ungureanu2005posttranslationalmodificationsin pages 65-68): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
18. (wilks2008thejakkinases pages 1-1): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
19. (wilks2008thejakkinases pages 3-4): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
20. (wilks2008thejakkinases pages 4-5): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
21. (wilks2008thejakkinases pages 6-8): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
22. (wilks2008thejakkinases pages 9-10): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
23. (wilks2008thejakkinases pages 9-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
24. (babon2014themolecularregulation pages 28-29): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
25. (babon2014themolecularregulation pages 3-4): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
26. (loris2007exploringstructureand pages 49-52): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
27. (mitra2010identificationofa pages 15-23): A Mitra. Identification of a novel cytokine inducible stat5 phosphoserine site (ps193) that positively regulates its transcriptional activity and is found constitutively …. Unknown journal, 2010.
28. (ungureanu2005posttranslationalmodificationsin pages 9-11): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
29. (wilks2008thejakkinases pages 8-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
30. (babon2014themolecularregulation pages 6-7): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
31. (babon2014themolecularregulation pages 7-9): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.